Note: Descriptions are shown in the official language in which they were submitted.
CA 02547194 2006-05-25
WO 2005/058276 PCT/EP2004/014465
-1-
"Pharmaceutical oral dosage form comprising a non-steroidal anti
inflammatory drug, and having good palatability"
*************
The present invention relates to a pharmaceutical oral dosage form
comprising a non-steroidal anti-inflammatory drug (NSAID), and having
good palatability.
More particularly, the present invention relates to an oral dosage
form comprising
- a NSAID selected from the group comprising ibuprofen, naproxen and
flurbiprofen,
- tromethamine, and
- a compound selected from the group comprising glycine, vitamine B6,
and mixtures thereof.
In the present description and in the claims, both the terms "NSAID"
and "non-steroidal anti-inflammatory drug" mean ibuprofen, naproxen
and flurbiprofen as racemate mixtures or as pure or enriched
enantiomer forms as well as pharmaceutically acceptable salts.
It is known that a number of non-steroidal anti-inflammatory drugs
(NSAIDs), such as ibuprofen, have a "chemesthetic effect" (irritant
effect) on the oral cavity, throat and pharynx (Breslin.et al. "Ibuprofen as
a chemesthetic stimulus: evidence of a novel mechanism of throat
irritation", Chem. Sens. 26:55-65, 2001 ).
This makes irritant and unpleasant the pharmaceutical dosage forms
for oral use containing ibuprofen, naproxen, flurbiprofen or enantiomers
and/or salts thereof, when such pharmaceutical forms are, for example,
partially swallowable or chewable tablets, orosoluble tablets, granulates
and powders to be suspended or dissolved before administration,
mouthwashes, sprays, cough drops, lozenges, syrups, drops, oral gels
and the like.
CONFLRMATION COPY
CA 02547194 2006-05-25
WO 2005/058276 PCT/EP2004/014465
_2_
In the present description and in the claims, the term "oral use"
embraces both systemic oral administration and topical oral
administration, and the term "oral form" means a pharmaceutical
dosage form for oral use.
Many investigations have been carried out so far to improve the
patient tolerability of oral forms based on ibuprofen, naproxen and
fluriprofen.
However, the ingredients that have been found to be capable of
reducing the irritant stimulus on the on the oral cavity, throat and
pharynx have also been found to give to the oral forms taste properties,
such as bitterness, saltiness and lye-taste, that resulted to be
unacceptable.
Therefore, there is still a great need for ingredients capable not only
of eliminating the throat-irritant stimulus, but also of giving an
acceptable taste, i.e. good palatability, to the oral forms based on
ibuprofen, naproxen or flurbiprofen.
Surprisingly it has now been found that this goal is achieved when a
compound selected from the group comprising glycine, vitamine B6 and
mixtures thereof, is added to an oral form comprising tromethamine and
a NSAID selected from the group comprising ibuprofen, naproxen and
flurbiprofen.
Therefore, in a first aspect the present invention relates to an oral
form comprising tromethamine and a NSAID selected from the group
comprising ibuprofen, naproxen and flurbiprofen, characterized in that it
also comprises a compound selected from the group comprising
glycine, vitamine B6 and mixtures thereof.
Preferably the amount of tromethamine ranges from 0.2 to 50 parts
by weight per 1 part by weight of NSAID. More preferably the amount of
tromethamine ranges from 1.4 to 2.5 parts by weight and, even more
C~~:!FIR,MATION COPY
CA 02547194 2006-05-25
WO 2005/058276 PCT/EP2004/014465
-3-
preferably, from 1.4 to 2.2 parts by weight per 1 part by weight of
NSAI D.
Preferably, the amount of glycine ranges from 0.01 to 20 parts by
weight per 1 part by weight of NSAID. More preferably, the amount of
glycine ranges from 0.0125 to 10 parts by weight per 1 part by weight of
NSAI D.
In turn, also the amount of vitamin B6 ranges from 0.01 to 20 parts
and, more preferably, from 0.0125 to 10 parts by weight per 1 part by
weight of NSAID.
Tolerability and palatability of the oral form of the present invention
have been investigated in vivo in man by means of the comparison
tests described hereinbelow.
The following examples are intended to further illustrate the
invention, without, however, limiting it in any way.
COMPARISON EXAMPLE 1
Solution A
Ingredients Amount (g)
Ibuprofen sodium 0.400
Demineralized water qs 100 ml
pH 7.0-7.5
COMPARISON EXAMPLE 2
Solution B
Ingredients Amount (g)
Flurbiprofen sodium 0.250
Demineralized water qs 100 ml
pH 7.0-7.5
COMPARISON EXAMPLE 3
Solution C
Ingredients Amount (g)
Naproxen sodium 0.220
Demineralized water qs 100 ml
COh~~~IRTUATION COPY
CA 02547194 2006-05-25
WO 2005/058276 PCT/EP2004/014465
-4-
COMPARISON EXAMPLE 4
Solution D
Ingredients Amount (g)
Ibuprofen sodium 0.400
Tromethamine 0,600
Demineralized water qs 100 ml
COMPARISON EXAMPLE 5
Solution E
Ingredients Amount (g)
Flurbiprofen sodium 0.250
Tromethamine 0,500
Demineralized water qs 100 ml
COMPARISON EXAMPLE 6
Solution F
Ingredients Amount (g)
Naproxen sodium 0.220
Tromethamine 0.400
Demineralized water qs 100 ml
INVENTION EXAMPLE 1
Solution G
Ingredients Amount (g)
Ibuprofen 0.400
Tromethamine 0.600
Glycin 0.200
Demineralized water qs 100 ml
INVENTION EXAMPLE 2
Solution H
Ingredients Amount (g)
Flurbiprofen 0.250
Tromethamine 0.500
Glycin 0.010
Demineralized water qs 100 ml
~'~P,'l-'t~~?~~~AT!CPJ COPY
CA 02547194 2006-05-25
WO 2005/058276 PCT/EP2004/014465
-5-
INVENTION EXAMPLE 3
Solution I
Ingredients Amount (g)
Naproxen sodium 0.220
Tromethamine 0.400
Glycin 0.145
Demineralized water qs 100 ml
INVENTION EXAMPLE 4
Water-soluble Granulate (L)
Ingredients Amount (g)
Ibuprofen 80 BP 0.400
Sodium saccharine 0.030
Tromethamine 0.600
Lemon flavouring Givaudan 96833-51 0.100
Acesulfame K 0.030
Vitamin B6 0.150
Sugar for tabletting 3.000
Sucrose monopalmitate 0.020
INVENTION EXAMPLE 5
Oral spray (M)
Ingredients Amount (g)
Flurbiprofen 0.250
Glycerol FU IX 10.000
95 ethyl alcohol 10.000
Sorbitol 70 7.000
Sodium saccharine 0.150
Tromethamine 0.500
Sodium benzoate 0.150
Tween 20 1.000
Mint cool flavour 0.195
Blu patent 0.0006
Glycin 0.010
CGNFIRMATICN COPY
WO 2005/058276 PCT/EP2004/014465
-6-
Demineralized water qs 100 ml
INVENTION EXAMPLE 6
Water-soluble Granulate (N)
Ingredients Amount (g)
Naproxen sodium 0.220
Sodium saccharine 0.032
Peppermint flavouring Givaudan 0.093
Acesulfame K 0.030
Maltitol 1.500
Glycin 0.145
Sucrose 1.500
Tromethamine 0.400
PALATABILITY TEST
The panel of individuals for the palatability (taste masking) test of the
oral forms under evaluation has been properly selected because the
irritation of the oral mucosae by the NSAIDs shows great individual
variability. Indeed, whereas for some individuals the irritation may be
"slightly noticeable", others define it as "strong" or "very strong" (Breslin
et al. "Ibuprofen as a chemesthetic stimulus: evidence of a novel
mechanism of throat irritation", Chem. Sens. 26:55-65, 2001 ).
There were therefore selected individuals who proved to be clearly
sensitive to the irritant action of the NSAIDs in the test disclosed
hereinafter.
Solutions A to C were administered to 40 individuals between 20 and
40 years old, and indications were given for correctly defining the
perceived irritant stimulus, as follows:
Stimulus Description
Burning Sensation generated by abrasion of the skin
or by exposure
to high temperature, or to the irritant action
of alcohol
Stinging Brief sensation produced as from an insect bite
or from thorns
'CGNFII~II~IATI~N COPY
CA 02547194 2006-05-25
WO 2005/058276 PCT/EP2004/014465
_7_
Sensation similar to that caused by the action
of small
Pricklingpenetrating needles
Diffuse sensation similar to the start of action
of an
Numbness anaesthetic (not an absence of sensation)
In addition, the 40 individuals were given instructions regarding the
following operating procedures:
- how to define the sensation perceived according to the terminology
defined in the preceding table,
- how to perform the operations of rinsing, swallowing and spraying of
the preparations and also how to recognize the background sensation
caused the preparations free of active principle.
Each of the 40 individuals was also requested to follow the standard
procedure hereinbelow when taking the preparations:
- sip 10 ml of demineralized water, hold it in the mouth for 10 seconds
and then swallow it,
- sip 10 ml of Solution, hold it in the mouth for 10 seconds and then
swallow it.
Next, the 40 individuals were asked to evaluate the intensity of the
irritation in the oral cavity and the perceived taste at time 0, at 30
seconds, 1 minute and 5 minutes after the administration, and 3 points
were assigned to those who defined the sensation as "strong", 2 points
to those who define defined the sensation as "moderate", 1 point to
those who defined the sensation as "mild" and 0 points to those who
defined the preparation as having no sensation.
Only the 18 individuals who received more than 40 points, and who
therefore had greater sensitivity of perception of the unpleasant
sensations generated by the NSAIDs, were thus selected.
These 18 individuals were requested to evaluate the palatability of
the solutions D to F as well as the aqueous solutions of the granulates L
and N and the oral spay M.
'CQ~;,'=!!~.M~,TInN COPY
CA 02547194 2006-05-25
WO 2005/058276 PCT/EP2004/014465
_$_
The procedure followed and the points assigned were as for those
described above, except that, in the case of the spray, the patients
sprayed in the mouth two puffs of 200 pl and then swallowed the
sprayed spray, whereas in the case of the granulate, each patient was
administered the content (average weight = 4.33 g) of a sachet
dissolved in 100 ml of water and stirred for 30 seconds.
In addition, the evaluation times were longer, since the 18 individuals
were requested to evaluate the intensity of the irritation in the mouth
and the perceived taste at time 0, at 30 seconds, 1 minute, 2 minutes, 3
minutes, 5 minutes, 10 minutes and 15 minutes after the administration.
The sum of the evaluations (0-15 minutes) for, respectively, the
burning, the stinging, the prickling and the numbness etc. was
calculated for each individual, along with the sum of the evaluations (0-
minutes) for all the sensations. These parameters were analysed by
15 the Wilcoxon "signed rank" method to compare the solutions and oral
forms containing the same active ingredient. The final scores are shown
in the following Table.
TABLE
Composition Active Ingredient Score
Solution A Ibuprofen 21
Solution D " 16
Solution G " 11
Granulate L " 8
Solution B Flurbiprofen 15
Solution E " 12
Solution H " g
Oral Spray M " g
Solution C Naproxen 20
Solution F " 17
Solution I " 10
CC3NF!RJ~1ATION COPY
CA 02547194 2006-05-25
WO 2005/058276 PCT/EP2004/014465
_g_
Granulate N I " 7
The evaluation of the compositions containing ibuprofen showed that
Solution G and the solution of Granulate L of the invention were less
irritant and unpleasant and had a better palatability than the comparison
Solutions A and D, not only for each individual sensation considered,
but also for the sum of the evaluations obtained for all the sensations.
The evaluation of the compositions containing flurbiprofen showed
that Solution H and the Oral Spray M of the invention were less irritant
and unpleasant and had a better palatability than the comparison
Solutions B and E, not only for each individual sensation considered,
but also for the sum of the evaluations obtained for all the sensations.
The evaluation of the compositions containing naproxen showed that
Solution I and the solution of Granulate N of the invention were less
irritant and unpleasant and had a better palatability than the comparison
Solutions C and F, not only for each individual sensation considered,
but also for the sum of the evaluations obtained for all the sensations.
25
CCNF'RMATI~N COPY
